Eli Lilly beats quarterly estimates, lifts full-year revenue forecast as Zepbound, Mounjaro sales surge
Obesity pill Foundayo misses Wall Street expectations despite overall strong demand
Eli Lilly reported third-quarter earnings and revenue that topped Wall Street expectations and raised its full-year sales outlook, driven by surging demand for its weight loss drug Zepbound and diabetes treatment Mounjaro, though sales of its new obesity pill Foundayo fell short of forecasts.